Date: 2012-05-02
Type of information: Grant
Company: Ark Therapeutics (UK)
Investors:
Amount: up to €6 million
Funding type: grant
Planned used: The grant supports, over six years, the consortium\'s involvement in a research programme to conclude final pre-clinical toxicology and initiate the clinical development of Ark\'s EG013 programme, its adenoviral vector containing a vascular endothelial growth factor (VEGF) gene in the treatment of fetal growth restriction during pregnancy.
Others: Ark Therapeutics Group has received notice of the award of an EU Framework Programme 7 Grant of up to €6 million to a consortium led by UCL in which Ark is the sole industrial partner engaged in the research.The consortium includes some of the leading fetal medicine centres across Europe.The grant is subject to the formal process of contract negotiation with the European Commission which is anticipated to reach conclusion in July 2012.
Therapeutic area:
